Validation and Optimization of Viral Clearance in a Downstream Continuous Chromatography Setting.

Continuous bioprocessing holds the potential to improve product consistency, accelerate productivity and lower cost of production. However, switching a bioprocess from traditional batch to continuous mode requires surmounting business and regulatory challenges. A key regulatory requirement for all biopharmaceuticals is virus safety, which is assured through a combination of testing and virus clearance through purification unit operations. For continuous processing, unit operations such as capture chromatography have aspects that could be impacted by a change to continuous multi-column operation; for example, do they clear viruses as well as a traditional batch single column. In this study we evaluate how modifying chromatographic parameters including the linear velocity and resin capacity utilization could impact virus clearance in the context of moving from a single column to multi-column operation. A Design of Experiment (DoE) approach was taken with two model monoclonal antibodies (mAbs) and two bacteriophages employed as mammalian virus surrogates. The DoE enabled the identification of best and worst-case scenario for virus clearance overall. Using these best and worst-case conditions, virus clearance was tested in single column and multi-column modes and found to be similar as measured by Log Reduction Values (LRV). The parameters identified as impactful for viral clearance in single column mode were predictive of multi-column modes. Thus, these results support the hypothesis that the viral clearance capabilities of a multi-column continuous Protein A system may be evaluated using an appropriately scaled-down single mode column and equipment. This article is protected by copyright. All rights reserved.